Radiofrequency ablation for the treatment of gastric antral vascular ectasia

Xavier Dray; Alessandro Repici; Pedro Gonzalez; Claus Fristrup; Stéphane Lecleire; Sergey Kantsevoy; Dov Wengrower; Peter Elbe; Marine Camus; Alessandra Carlino; Francisco Pérez-Roldán; Tomer Adar; Philippe Marteau

doi:10.1055/s-0034-1377695

Endoscopy, Inhaltsverzeichnis

Endoscopy 2014; 46(11): 963-969
DOI: 10.1055/s-0034-1377695

Innovations and brief communications

Radiofrequency ablation for the treatment of gastric antral vascular ectasia

Xavier Dray

¹APHP Lariboisière Hospital and Sorbonne Paris Cité Paris 7 University, Paris, France

,

Alessandro Repici

²Istituto Clinico Humanitas, Milano, Italy

,

Pedro Gonzalez

³Hospital General Mancha Centro, Alcazar de San Juan, Spain

,

Claus Fristrup

⁴Odense University Hospital, Odense, Denmark

,

Stéphane Lecleire

⁵Rouen University Hospital, Rouen, France

,

Sergey Kantsevoy

⁶Mercy Medical Centre, Baltimore, Maryland, United States

,

Dov Wengrower

⁷Shaare Zedek Medical Centre and Hebrew University Medical School, Jerusalem, Israel

,

Peter Elbe

⁸Karolinska University Hospital, Stockholm, Sweden

,

Marine Camus

¹APHP Lariboisière Hospital and Sorbonne Paris Cité Paris 7 University, Paris, France

,

Alessandra Carlino

²Istituto Clinico Humanitas, Milano, Italy

,

Francisco Pérez-Roldán

³Hospital General Mancha Centro, Alcazar de San Juan, Spain

,

Tomer Adar

⁷Shaare Zedek Medical Centre and Hebrew University Medical School, Jerusalem, Israel

,

Philippe Marteau

¹APHP Lariboisière Hospital and Sorbonne Paris Cité Paris 7 University, Paris, France

› Institutsangaben

Abstract

Background and study aims: The traditional endoscopic treatment for gastric antral vascular ectasia (GAVE) is argon plasma coagulation, but results are not always positive. Radiofrequency ablation (RFA) is a new endoscopic therapy that may be an attractive option for the treatment of GAVE. The aim of this study was to assess the efficacy and safety of RFA for the treatment of GAVE.

Patients and methods: This was an open-label, retrospective, case series study. The main outcome measures were number of red blood cell (RBC) packs transfused (transfusion requirement) and hemoglobin concentrations (g/dL) in the 6 months prior to and after RFA. Success was defined as a decrease in transfusion requirement in the 6 months after RFA compared with before treatment.

Results: A total of 24 patients underwent a mean of 1.8 ± 0.8 RFA sessions. No complications were reported. One patient was referred for additional argon plasma coagulation during follow-up. The mean number of RBC packs decreased in all 23 transfusion-dependent patients, from a mean of 10.6 ± 12.1 during the 6 months prior to RFA, to a mean of 2.5 ± 5.9 during the 6 months after RFA treatment (P < 0.001), and 15 patients (65.2 %) were weaned off transfusions completely. An increase in the hemoglobin concentration was reported in all patients after RFA (from 6.8 ± 1.4 g/dL to 9.8 ± 1.8 g/dL; P < 0.001).

Conclusion: RFA for the treatment of GAVE seems feasible and safe, and significantly reduced the need for RBC transfusion and increased the hemoglobin level in this retrospective case series.

Volltext

Referenzen

References
1 Sebastian S, O’Morain CA, Buckley MJM. Review article: current therapeutic options for gastric antral vascular ectasia. Aliment Pharmacol Ther 2003; 18: 157-165
2 Gross SA, Al-Haddad M, Gill KRS et al. Endoscopic mucosal ablation for the treatment of gastric antral vascular ectasia with the HALO90 system: a pilot study. Gastrointest Endosc 2008; 67: 324-327
3 McGorisk T, Krishnan K, Keefer L et al. Radiofrequency ablation for refractory gastric antral vascular ectasia (with video). Gastrointest Endosc 2013; 78: 584-588
4 Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion 2008; 77: 131-137
5 Dulai GS, Jensen DM. Treatment of watermelon stomach. Curr Treat Options Gastroenterol 2006; 9: 175-180
6 Shibukawa G, Irisawa A, Sakamoto N et al. Gastric antral vascular ectasia (GAVE) associated with systemic sclerosis: relapse after endoscopic treatment by argon plasma coagulation. Intern Med 2007; 46: 279-283
7 Yusoff I, Brennan F, Ormonde D et al. Argon plasma coagulation for treatment of watermelon stomach. Endoscopy 2002; 34: 407-410
8 Chaves DM, Sakai P, Oliveira CV et al. Watermelon stomach: clinical aspects and treatment with argon plasma coagulation. Arq Gastroenterol 2006; 43: 191-195
9 Herrera S, Bordas JM, Llach J et al. The beneficial effects of argon plasma coagulation in the management of different types of gastric vascular ectasia lesions in patients admitted for GI hemorrhage. Gastrointest Endosc 2008; 68: 440-446
10 Gostout CJ, Viggiano TR, Ahlquist DA et al. The clinical and endoscopic spectrum of the watermelon stomach. J Clin Gastroenterol 1992; 15: 256-263
11 Bjorkman DJ, Buchi KN. Endoscopic laser therapy of the watermelon stomach. Lasers Surg Med 1992; 12: 478-481
12 Liberski SM, McGarrity TJ, Hartle RJ et al. The watermelon stomach: long-term outcome in patients treated with Nd:YAG laser therapy. Gastrointest Endosc 1994; 40: 584-587
13 Kantsevoy SV, Cruz-Correa MR, Vaughn CA et al. Endoscopic cryotherapy for the treatment of bleeding mucosal vascular lesions of the GI tract: a pilot study. Gastrointest Endosc 2003; 57: 403-406
14 Kruger R, Ryan ME, Dickson KB et al. Diffuse vascular ectasia of the gastric antrum. Am J Gastroenterol 1987; 82: 421-426
15 Spahr L, Villeneuve JP, Dufresne MP et al. Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. Gut 1999; 44: 739-742
16 Rustagi T, Corbett FS, Mashimo H. Treatment of chronic radiation proctopathy with radiofrequency ablation (with video). In press 2014. Gastrointest Endosc